Mycotopia Therapies, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Mycotopia Therapies, Inc. has filed its 2023 10-K report detailing financial data and corporate structure.</b>

AI Summary

Mycotopia Therapies, Inc. (AIBT) filed a Annual Report (10-K) with the SEC on April 23, 2024. Mycotopia Therapies, Inc. (formerly 20/20 Global, Inc.) filed its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Nevada and operates within the Medicinal Chemicals & Botanical Products sector. The filing covers the period from January 1, 2023, to December 31, 2023. Key financial statement elements like Preferred Stock, Common Stock, Additional Paid-In Capital, and Retained Earnings are detailed for fiscal years 2021, 2022, and 2023. The report also references specific assets such as Equipment and Intellectual Property as of December 31, 2023.

Why It Matters

For investors and stakeholders tracking Mycotopia Therapies, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Mycotopia Therapies' financial performance and position for the fiscal year 2023, crucial for investors to assess the company's health and future prospects. The detailed breakdown of equity accounts and asset types offers insights into the company's capital structure and operational assets, which are important for understanding its business model and potential growth drivers.

Risk Assessment

Risk Level: medium — Mycotopia Therapies, Inc. shows moderate risk based on this filing. The company's financial health and operational status are not detailed in the provided text, making it difficult to assess its current risk profile beyond the standard disclosures expected in a 10-K filing.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management discussion to make informed investment decisions.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-23 — Filing Date (Date of submission)
• 2023-01-01 — Reporting Period Start (Fiscal year start)
• 2022-12-31 — Prior Year End (Comparison period)

Key Players & Entities

• Mycotopia Therapies, Inc. (company) — Filer name
• 20/20 Global, Inc. (company) — Former company name
• NV (location) — State of incorporation
• 2833 (industry) — Standard Industrial Classification (Medicinal Chemicals & Botanical Products)
• 03 Life Sciences (company) — Organization name
• 870645794 (identifier) — IRS Number
• 2024-04-23 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end

FAQ

Industry Context

Mycotopia Therapies operates in the Medicinal Chemicals & Botanical Products industry, which involves the development and production of pharmaceutical products derived from medicinal plants and chemicals.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information about their business, financial condition, and operations.

What Investors Should Do

1. Review the full 10-K for detailed financial statements and performance metrics.
2. Analyze the risk factors section for potential challenges and uncertainties.
3. Investigate any disclosed executive compensation or significant corporate actions.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the annual financial statements.
• 2024-04-23: 10-K Filing Date — Date the annual report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing analyzed, so no comparison to a previous filing is available.

Key Financial Figures

• $0.001 — g) of the Act: Common Stock, Par Value $0.001 (Title of class) Indicate by check m
• $0 — stock to 100,000,000 shares, par value $0.001, and to authorize 5,000,000 shares
• $10.75 billion — lly over the next seven years, reaching $10.75 billion in 2027 1 . Several companies are runni
• $6.85 billion — US market for psychedelics could reach $6.85 billion in 2027. It was the Company's intent t
• $350,000 — de for: (i) 20/20 Global's purchase for $350,000 in cash of all of the outstanding stock
• $2,000,000 — "Preferred Stock") with a face value of $2,000,000, convertible into shares of the Company
• $7,000,000 — result in the employees receiving up to $7,000,000 of the Preferred Stock over a three-yea

Filing Documents

• tpia-20231231.htm (10-K) — 737KB
• tpia_ex31z1.htm (EX-31.1) — 6KB
• tpia_ex32z1.htm (EX-32.1) — 4KB
• tpia10k_1.jpg (GRAPHIC) — 6KB
• tpia10k_2.jpg (GRAPHIC) — 3KB
• 0001096906-24-000907.txt (&nbsp;) — 3545KB
• tpia-20231231_cal.xml (EX-101.CAL) — 20KB
• tpia-20231231_def.xml (EX-101.DEF) — 90KB
• tpia-20231231_lab.xml (EX-101.LAB) — 188KB
• tpia-20231231_pre.xml (EX-101.PRE) — 182KB
• tpia-20231231.xsd (EX-101.SCH) — 44KB
• tpia-20231231_htm.xml (XML) — 441KB

BUSINESS

ITEM 1. BUSINESS The following description of our business contains forward-looking statements relating to future events or our future financial or operating performance that involve risks and uncertainties, as set forth above under "Special Note Regarding Forward-Looking Statements." Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors described in the Annual Report, including those set forth above in the Special Cautionary Note Regarding Forward-Looking Statements or under the heading "Risk Factors" or elsewhere in this Annual Report. Business Overview Mycotopia Therapies, Inc. promotes the study of psychedelics for the treatment of mental health issues and supports the creation of both natural and synthetic molecules for the development of appropriate treatments. Mycotopia also intends to deploy technology from its parent company, Ehave, Inc., in the collection of research and clinical data to further the study of the effects of psychedelics in the treatment of mental health issues. With the acquisition of assets from Philon Labs, we intend on using Artificial Intelligence ("AI") to transform great ideas and innovative solutions into disruptive products using advanced engineering and design techniques, enhancing patient care and streamlining medical processes. History Mycotopia Therapies, Inc., a Nevada corporation (the "Company"), was incorporated in the State of Nevada on January 21, 2000, under the name RM Investors, Inc. In March 2014, under the terms of an Exchange Agreement and Plan of Reorganization, we acquired 100% of the issued and outstanding shares of our subsidiary 20/20 Produce Sales, Inc., an Idaho corporation that was incorporated on December 22, 1994. On March 26, 2014, we amended and restated our articles of incorporation to increase our authorized shares of common stock to 100,000,000 shares, par value $0.001, and to authorize 5,000,000 shares of preferred

View Full Filing

View this 10-K filing on SEC EDGAR